To date, the inhibition of the renin–angiotensin–aldosterone system (RAAS) and the sympathetic nervous system (SNS) by angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers (ACE-I/ARBs) and beta-blockers (BBs) has been the cornerstone of drug therapy for HF with reduced ejection fraction (HFrEF) [3]. This evidence concerns the gene ACE and hydrops fetalis.